Our investigation was carried out to assess the protective impact beside the antioxidant role of vitamin E on Moxifloxacin's possible adverse effects. Collection of blood samples at 1st, 7th, 14th, 21st days after treatment. Collection of tissue samples at 7th and 14th days after treatment to evaluate the protective effect of Vit. E. Our results showed (day 14moxifloxacin): multifocal hepatic necrosis of variable sizes, partially replaced by macrophages occasionally with giant cells formation. The hepatic blood vessels were moderately congested and the bile ducts were proliferated with characteristic portal round cells aggregation and portal fibrosis. Examined sections from kidney showed cystic dilatation of few tubules in the medulla and cortex. The renal pelvis revealed focal sloughing and hyperplasic changes in the transitional epithelium. Focal interstitial and perivascular aggregation of round cells and eosinophils were observed. The renal blood vessels were mildly congested. Day 14 moxifloxacin and Vit. E: sections showed normal hepatic parenchyma with residual portal biliary proliferation and fibrosis. Minute focal hepatic necrotic areas partially replaced by round cells were also seen. Also showing apparently normal nephron units with mild degenerative changes in some tubular epithelium and cyst dilatation in some renal tubules. Therefore, Vitamin E should be taken with moxifloxacin to decrease its adverse effects.